NCT00637949View on ClinicalTrials.gov

Safety of Lumiracoxib in Patients With Osteoarthritis

PHASE3CompletedINTERVENTIONAL
Enrollment

309

Participants

Timeline

Start Date

December 31, 2000

Primary Completion Date

March 31, 2001

Study Completion Date

March 31, 2001

Conditions
Osteoarthritis
Interventions
DEVICE

lumiracoxib

400 mg once daily, oral over 6 weeks

DRUG

rofecoxib

25 mg, oral, daily over 6 weeks

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY

NCT00637949 - Safety of Lumiracoxib in Patients With Osteoarthritis | Biotech Hunter | Biotech Hunter